Seeking AlphaCodex · 实盘不做把握 5/10
北京时间·🕒 发布 21:25:09时区推断·⟳ 抓取 21:30:07·⚡ 决策 07-22 21:32:48 +2m41s·96.9 天前
Dr. Reddy's Q1收入8.53亿美元、同比降5.5%，小幅超预期
收入8.53亿美元仅较预期高759万美元，同时同比下降5.5%，不是明确正向财报惊喜。
📄 原文Seeking Alpha↗ 原文
Dr. Reddy's GAAP EPS of $0.06, revenue of $853M beats by $7.59M
- Dr. Reddy's press release (RDY): Q1 GAAP EPS of $0.06. - Revenue of $853M (-5.5% Y/Y) beats by $7.59M. - Operating Wo…
不做 Dr. Reddy's（RDY.US）
财报收入仅小幅超预期且同比下降，缺少明确超预期指引或可量化短线正向edge，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 财报摘要显示Q1收入8.53亿美元、同比下降5.5%，仅小幅高于预期。
关键理由
- 收入8.53亿美元仅较预期高759万美元，同时同比下降5.5%，不是明确正向财报惊喜。
- EPS为0.06美元，正文未给出相对一致预期的显著超预期幅度。
主要风险
- 财报类事件默认需验证超预期幅度与指引，本条只有小幅收入beat且ROCE偏低。
原文全文
展开原文 · 547 字
- Dr. Reddy's press release (RDY): Q1 GAAP EPS of $0.06.
- Revenue of $853M (-5.5% Y/Y) beats by $7.59M.
- Operating Working Capital: As on 30th June 2026 at ₹143.5 billion.
- Capital Expenditure: Q1FY27 at ₹3.1 billion.
- Cash Flow (before acquisition related payout): Q1FY27 at ₹(2.2) billion.
- Net Cash Surplus: As on 30th June 2026 at ₹30.6 billion.
- Net Debt to Equity: As on 30th June 2026 is (0.08).
- Annualised Return on Capital Employed (RoCE): Q1FY27 stood at 5.3%. Excluding the semaglutide API related impact, annualised RoCE at 8%.
- Revenue of $853M (-5.5% Y/Y) beats by $7.59M.
- Operating Working Capital: As on 30th June 2026 at ₹143.5 billion.
- Capital Expenditure: Q1FY27 at ₹3.1 billion.
- Cash Flow (before acquisition related payout): Q1FY27 at ₹(2.2) billion.
- Net Cash Surplus: As on 30th June 2026 at ₹30.6 billion.
- Net Debt to Equity: As on 30th June 2026 is (0.08).
- Annualised Return on Capital Employed (RoCE): Q1FY27 stood at 5.3%. Excluding the semaglutide API related impact, annualised RoCE at 8%.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。